Wildlife and nature

Animal shelters and rescues

Theater and dance

Rivers, parks and trails

Hunger and food

Schools and learning

Housing and homelessness

Community health

Mental health

Mentoring and foster care

Legal help and rights

Jobs and money help

Atlanta

The Triangle

Everywhere

The Collective Workshop

Royal Animal Refuge

Asian Americans Advancing Justice-Atlanta

Georgia Advancing Communities Together

Atlanta Writers Club

Cobb Collaborative

Bosleys Place

Jewish Fertility Foundation

We are a patient-driven organization that seeks a cure for ALK+ cancer and works to improve patients’ quality of life and life expectancy worldwide.
ALK Positive, Inc. is a patient-founded and patient-driven nonprofit organization committed to transforming the future for everyone affected by ALK-positive cancer. What began in 2015 as a grassroots effort by Merita Carroll, a stage IV patient and oncology nurse seeking connection, has grown into a global movement of more than 3,000 patients and care partners across 55+ countries.
We’re not just here to raise awareness, we’re here to drive research, fund clinical trials, and demand better treatment options . From advocating for the inclusion of ALK in clinical studies to investing in breakthrough science, we act with urgency, because for our community, research means survival.
This is more than an organization. It’s a global force for change, made possible by dedicated volunteers, bold leadership, and a community that refuses to wait.
ALK Positive was created by Merita Carroll in 2015. She wanted a support community where ALK-positive lung cancer patients, like herself, and caregivers could share their personal experience with this condition.
Merita was a vibrant healthy young woman working as a registered nurse when diagnosed Stage IV. She was diagnosed on March 6, 2015 and, sadly, passed away on April 24, 2018.

Chair Yoga

Art Therapy

Young ALKies

Explore with Writing

Tail Gate Chat

Non-Metastatic ALKies

ALKtALK Season 7: Car T Cells to Eradicate Oncogene Driven Lung Cancer

ALKtALK Season 7: What's New in Alk Research and What It Could Mean for You

ALKtALK Season 7 Premiere

Clinical Trials Connect: A Year of Progress in Alk Research

Give

SIGN UP TODAY

Clinical Trials Update: Can GLP-1’s Tackle Lorlatinib Weight Gain?

Patient Spotlight: Matt Hiznay

Baked Honey Glazed Carrots Recipe

2025 Worldwide ALK TKI Revenues Exceed Three Billion Dollars

NXP900 + Lorlatinib: Blocking a Potential ALK Bypass Pathway

ALK Positive, Inc. Sponsors Real-World Registry that Confirms the Success of Modern ALK Therapy, and the Contribution of ALK Positive’s Collaborative Clinical Trial Efforts.

New Phase 1 Trial Will Explore AQUA07 in ALK-positive NSCLC

Clinical Trials Update: ALK Research Makes a Big Splash @ The ASCO Conference

Strawberry Goat Cheese Crostini

Patient Spotlight: Laura Reed

GET THE PDF

Dr. Ken Culver

Kirk Smith

Summer Farmen

Christina Weber

Nancee Pronsati

Teresa Wiant

Jeffrey Sturm

Greg Wehn

Duncan Preece

Amanda Bialack-Stewart

Debbi Martinez

Yvonne Diaz

Marc Muskavitch

Thomas Carroll

Dr. Mark Awad

Dr. Ross Camidge

Beau Bolton

Jaden Southard

John Pender

Myna Kota

Merita Carroll

Roberta Plantak

Katie Delaney

Sadia Yaakov

Seven years of research. Seven years of progress. 💙 What do the latest CROWN study results mean for people living with ALK-positive lung cancer? The findings offer an important look at long-term cancer control, including protection against cancer progression in the brain, and what these advances could mean for patients and their families. We're especially proud that ALK Positive Treasurer and ALK-positive patient Nancee Pronsati, alongside fellow patient advocate Debra Montague, helped co-author a new plain-language summary of the seven-year results. Together, they're helping make complex research more accessible while bringing attention to what matters to patients: brain health, managing side effects, quality of life, and planning for the future. Because research isn't just about how long a treatment works. It's about what that time makes possible. 💙 Swipe through to explore the findings and read the full summary: https://doi.org/10.1080/14796694.2026.2734063 #ALKPositive #LungCancerResearch #CROWNStudy

What does more time make possible? 💙 Another adventure. A trip to the beach. More ordinary moments with loved ones. Another World Series championship. For people living with ALK-positive lung cancer, these are more than dreams. They're the moments and experiences they hope to have more of. Today, on ALK-Positive Lung Cancer Awareness Day, we're sharing the voices of people in our community and the futures they're still dreaming of. Research has already changed what it means to live with ALK-positive lung cancer, bringing more treatment options and more time. But there is still so much more to discover. More Research = More Dreams. This Lung Cancer Awareness Month, help us reach our $2 million goal to fund research that makes more futures possible. Thanks to a generous donor, every gift is matched, doubling your impact. 💙 Give today: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #ALKPositive #LungCancerAwarenessMonth

Dr. Jessica J. Lin, Program Director of Thoracic Medical Oncology at Mass General Brigham Cancer Institute, leads clinical research on ALK+ lung cancer at @massgeneralbrigham. Her work explores why tumors become resistant to targeted therapies, and on developing next-generation treatments to overcome that resistance. She knows firsthand that research is the key to realizing the dream that she and her patients share: a cure. #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

Research doesn't stop, and neither do we! 🔬 Our Executive Director and Medical Director, Dr. Ken Culver, is in Phoenix, Arizona, this week, attending the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting! SITC brings together leading researchers, clinicians, and innovators from around the world to share the latest advances in cancer immunotherapy. For our ALK-positive community, staying connected to emerging science is an important part of our mission. From new immunotherapy approaches to research exploring how we can overcome treatment resistance, we're always looking ahead to what could mean more treatment options for patients. We're excited to have Ken there, learning, connecting, and bringing the patient perspective into conversations about the future of cancer research. Because More Research = More Dreams. 💙 Learn more about SITC 2026: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule #SITC2026 #ALKPositive #LungCancerAwarenessMonth #MoreResearchMoreDreams #CancerResearch

For parents with ALK+ lung cancer—like Erin, from Roanoke, VA—the dream is simple. She wishes for more time with family, to see her kids continue to grow into themselves and thrive. Erin has lived with ALK+ cancer for 5 years. Help her—and patients around the world—share many more special moments with their loved ones. 💙 This Lung Cancer Awareness Month, you can help make more dreams possible. Every gift will be matched by a generous donor, doubling your impact. https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams

More options. More time. More life. More dreams. 💙 For people living with ALK-positive cancer, clinical trials represent more than advancing research. They offer the possibility of new treatment options, renewed hope, and more time to do the things we love with the people we love. In this video, Michael Hu shares his personal experience with clinical trials and why having access to new treatment options matters so much. Clinical trials are an important part of cancer care, and exploring them doesn’t have to be overwhelming. Whether you’re newly diagnosed or considering what’s next, learning about clinical trials can help you have informed conversations with your care team. 💙 Wondering what clinical trials might be available to you? Our ALK Clinical Trial Finder makes it easier to explore trials that include ALK-positive cancer, both near you and around the world. Visit ALKPositive.org to learn more and explore your options. Because every new discovery brings the possibility of more options, more time, and more dreams to live. More Research = More Dreams.

Greg, from Huntsville, AL, has lived with ALK+ lung cancer for 5 years. And while he’s continued to advocate and take on new adventures, his future, like that of most patients, is uncertain, with treatment unending and eventual resistance a stark reality. He dreams of freedom from cancer—from symptoms, treatments, and fears. Help Greg and patients like him live longer, fuller lives without the burden of illness by supporting research that has the potential to transform lives. Donate Now: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

ALK Positive and our medical community are devoted to improving outcomes for people with ALK+ cancer all over the world. Dr. Ben Solomon of Peter MacCallum Cancer Centre in Melbourne, Australia, has helped lead the clinical trials behind three generations of ALK-targeted therapies—research that has dramatically extended lives and improved quality of life. His vision goes further: a future where lung cancer is curable—for every patient. Thank you, Dr. Solomon, for all you do to help us get to our dream of a cure. #MoreResearchMoreDreams #LungCancerAwarenessMonth

Loida, a Para powerlifter from Spain, has competed at the last 5 Paralympic Games and is a European medalist. In 2023, she was diagnosed with ALK+ lung cancer. Because of research, many people with ALK+ cancer can live full, active lives while undergoing treatment, and Loida dreams of being here for the 2028 Games. Help her get there, still thriving, by supporting research that makes better, life-extending treatments—and ultimately a cure—possible. Donate: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

@christine.lovly , Division Chief, Thoracic Medical Oncology, City of Hope National Medical Center, is on the front lines of treatment for people with ALK+ lung cancer, working hard to propel the field forward and create better outcomes for patients. She is a leading authority on why tumors become resistant to targeted therapies, research supported by ALK+ Positive. Her dream reaches past a cure, to a world where no one has to endure this disease. Thank you, Dr. Lovly, on everything you're doing to make our dream of a cure possible. #MoreResearchMoreDreams #LCAM @cityofhope

Debbi, who was diagnosed with ALK+ lung cancer in 2018, has shared in 8 years of celebrations—and all the everyday magic in between—because of research. For people with ALK+ cancer, every birthday, holiday, graduation, and special moment spent with loved ones is a win, never taken for granted. Debbi dreams of being here for many more milestones, and wants the same for all ALK+ patients. Donate to support the memories that make all the difference: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

“We all dream of a better world. Cancer research is how we can turn some dreams into realities.” — Dr. Ross Camidge Dr. Ross Camidge, Director of Thoracic Oncology at the University of Colorado Cancer Center, has spent decades as a leader in lung cancer research and care, including advancing treatments for ALK-positive lung cancer. In 2022, he was diagnosed with advanced lung cancer himself. Few understand the impact of this disease, or have helped shape the landscape of care, quite like Dr. Camidge. His words remind us why research matters. Every new discovery brings us closer to turning more dreams into realities. Thank you, Dr. Camidge, for helping make those dreams possible. #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

For 10 years, Colin Barton has not only lived with ALK+ lung cancer but also worked to change lives for fellow patients around the world. Since ALK Positive’s earliest days, he has been a champion of research as both an advocate and a donor. His support has helped propel powerful advances in treatment, extending lives by years and improving quality of life for thousands. He says, “I support ALK Positive Inc. with my time and funds because it is the world’s premier organization for improving the lives of ALK-positive cancer patients now and in the future. Every year it has more impact.” Today, Colin dreams of a cure—and researchers are getting closer every day. Follow Colin’s example and be part of life-changing progress. Donate: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

More Research = More Dreams. 💙 What do you dream more research will make possible? Watching your children grow up. Making music. Exploring new places. Growing stronger. One day being able to say, “I'm cured.” For people living with ALK-positive cancer, these aren't just dreams. They're the moments, milestones, and futures they hope to experience. Today marks the beginning of Lung Cancer Awareness Month, and we're launching our More Research = More Dreams campaign with a goal of raising $2 million to advance ALK-positive cancer research. Because research is about more than scientific discoveries. It's about the people waiting for the next breakthrough, the families hoping for more time together, and the possibilities that new treatments can bring. Every dream deserves a chance. Watch our community share what they're dreaming of, and join us in making more dreams possible. 💙 Donate today: https://secure.qgiv.com/event/moredreams/donate/ #MoreResearchMoreDreams #LungCancerAwarenessMonth #ALKPositive

🔬 Help Advance CAR T-Cell Research for Oncogene-Driven Lung Cancer On October 18, over 200 patients, care partners, and advocates from the ALK-positive, EGFR, HER2, and broader oncogene-driven lung cancer communities joined ALKtALK, in collaboration with EGFR Resisters, to hear Dr. Kyle Concannon from the University of Colorado Anschutz Medical Campus. He shared his work on active-conformation EGFR-specific (ACES) CAR T cells, a new approach designed to find and attack the cancer cells that survive targeted therapy. For many of us, that is the question that matters most. ALK inhibitors have given us more time than ever before, but resistance remains the reality we all live with. CAR T-cell therapy has already changed what is possible for some blood cancers. Dr. Concannon’s research asks whether engineered immune cells could do the same for oncogene-driven lung cancer, and possibly work alongside the targeted therapies we already rely on. The ACES program includes ALK-positive and EGFR arms, and our communities have the chance to help move it forward. Research at this stage is needed to build the evidence for a first clinical trial. This research is still early. That is exactly why patient-funded support matters: early-stage science is often the hardest to fund, and our communities can help shape what gets studied and how quickly. Together, we can help create more possibilities for people living with oncogene-driven lung cancer. Watch the ALKtALK replay to learn more about Dr. Concannon's research and how our communities can help move this work forward. ▶️ https://youtu.be/30skcFExCPA?si=KV6bYX9ZGY0gB63X Stay informed. Become empowered.

Feeling overwhelmed by the practical and financial challenges that come with living with ALK-positive cancer? Our partner, Triage Health, is hosting a FREE conference for patients, caregivers, and health care professionals. Nov 6 & 7 TriageHealth.org/Conferences #TriageTalks #HealthCareRight

What’s got our Executive Director Ken Culver excited about the future of ALK+ lung cancer? Reporting from #ESMO26 in Madrid, Ken shares some of the research, conversations and collaborations giving our community reasons to be hopeful. From Dr Ben Solomon’s latest CROWN trial insights into how circulating tumor DNA (ctDNA) could help identify patients who may benefit from more intensive treatment, to exciting conversations with biotech and pharmaceutical companies working on the next generation of therapies. And beyond the science, a special highlight: bringing together 40 advocates from around the world to strengthen collaboration through our emerging Global ALK+ Alliance. The science is moving forward. Our global community is growing stronger. And together, we’re working to ensure that progress reaches everyone living with ALK+ cancer, wherever they live. #LungCancer #cancer #stage4 #research

One dinner out can make a difference! 💚 Each year, Kelly and her dad, Larry, bring friends, family, coworkers, and neighbors together for a Red Robin Dine and Donate fundraiser supporting ALK-positive cancer research. Their idea is simple: choose a date, spread the word, and bring people together for a great cause. And that's the beauty of community fundraising. There are so many ways to get involved! A dinner out. A game night. A birthday celebration. A personal fundraising page. Whatever your idea, you can turn it into an opportunity to support research and help create more treatment options for people living with ALK-positive cancer. This Lung Cancer Awareness Month, we're working toward $2 million for ALK+ cancer research through our More Research = More Dreams campaign, and we'd love for you to be part of it. 💚 Ready to get started? Explore fundraising ideas, watch Kelly and Larry's full story, and find the resources to bring your own idea to life. 👉 https://alkpositive.org/fundraise-with-alk/ #MoreResearchMoreDreams #ALKPositive #LungCancerAwarenessMonth #FundraiseForResearch @RedRobin

We're proud to partner with Triage Cancer for the Triage Health Conference. This FREE event covers health insurance, advocacy, managing finances, and more. Health care professionals can earn free CE credits. Nov 6 & 7| Online TriageCancer.org/Conferences #TriageTalks #HealthCareRights

Honoring an extraordinary physician, researcher, and friend to the ALK-positive community. ALK Positive is proud to announce a $50,000 gift to the Ross Camidge, MD, PhD, Thoracic Oncology Endowed Program Support Fund at the University of Colorado Anschutz Medical Campus. Dr. Ross Camidge has dedicated decades to advancing lung cancer research, improving treatment options, and caring for patients around the world. His innovative thinking, compassion, and commitment to pushing the boundaries of cancer care have made a lasting impact on our community. This gift is more than a tribute. It's an investment in the future of thoracic oncology, supporting continued research, patient care, education, and the next generation of physicians and researchers. We are deeply grateful for all Dr. Camidge has done and proud to help ensure the work he has inspired continues for years to come. 🔗 Read the full announcement: https://alkpositive.org/blog/alk-positive-donates-50000-to-honor-dr-ross-camidge-and-support-the-future-of-thoracic-oncology/ #ALKPositive #LungCancerResearch #ThoracicOncology #ALKPositiveCancer

🌍 ALK Positive is headed to ESMO Congress 2026! Dr. Ken Culver and Yvonne Diaz will be in attendance October 20–27, connecting with leading physicians, researchers, and global partners to advance ALK-positive cancer research and amplify the voices of patients worldwide. 💚 Every connection is an opportunity to strengthen collaboration, accelerate research, and help bring more treatment options to people living with ALK-positive cancer. 👋 Attending ESMO? Be sure to say hello to Ken and Yvonne! We'd love to connect. #ESMO2026 #ALKPositive #LungCancerResearch #PatientAdvocacy

🧬 Could CAR T-cell therapy offer a new way to treat lung cancer? It’s already transforming treatment for some blood cancers. Now researchers are exploring whether CAR T-cell therapy could help tackle lung cancer, including cancers that develop resistance to targeted therapies. Join ALK Positive and EGFR Resisters tomorrow (Sunday, Oct 18th) for a special joint ALKtALK with Dr Kyle Concannon, thoracic oncologist and physician-scientist at the University of Colorado Anschutz Medical Campus. Dr Concannon and team are developing ACES CAR T cells, an experimental approach with potential applications across ALK, EGFR, HER2 and other oncogene-driven lung cancers. 💙 What makes this research particularly exciting? It explores whether specially engineered immune cells could offer an entirely different way to target cancer cells. We’ll discuss how the science works, where the research stands today and what needs to happen before the first clinical trial. 🎤 Plus, a live Q&A with Dr Concannon! Bring your questions and hear directly from the scientist developing this approach. 📅 Sunday, October 18 ⏰ 7 p.m. ET 🔗 Register through the link in our bio! Many patient communities. One shared goal: more treatment options for everyone. 💙 #ALKPositive #EGFR #LungCancer #CARTCellTherapy

🎥 The ALKtALK Replay is Now Available! What’s new in ALK-positive cancer research, and what could it mean for you? In our latest ALKtALK, Dr. Ken Culver, Executive Director and Medical Director of ALK Positive, shares updates on new clinical trials, emerging research, and projects supported by or connected to the ALK-positive community. 🔬 From new treatment approaches to ongoing research efforts, learn what’s happening in ALK-positive cancer research and how this work could help create more options for patients. 💚 Plus, get a special preview of More Research = More Dreams, our upcoming Lung Cancer Awareness Month campaign, and discover how you can get involved this November! ▶️ Watch the full ALKtALK replay now on our YouTube channel: https://www.youtube.com/watch?v=r3ocrSEb-jc #ALKPositive #ALKtALK #LungCancerAwarenessMonth #MoreResearchMoreDreams

What does survivorship mean when you're living with ALK-positive cancer? Survivorship is about more than a diagnosis or treatment. It's about living, adapting, and finding ways to maintain quality of life along the way. In this clip from our Season 7 premiere of ALKtALK, Dr. Eric Singhi, thoracic medical oncologist at MD Anderson Cancer Center, shares his perspective on what cancer survivorship means for the ALK-positive community. In the full conversation, Dr. Singhi also discusses building a multidisciplinary care team, advances in lung cancer research, and practical questions about TKIs, cancer progression, vaccines, and more. Whether you're newly diagnosed or have been living with ALK-positive cancer for years, this conversation offers valuable information and perspective on navigating life after diagnosis. 🎥 Watch the full ALKtALK replay: https://youtu.be/aIVlb1OiWxU #ALKPositive #ALKtALK #CancerSurvivorship #LifeWithALKPositiveCancer

How could we find new cancer treatments faster? ALK Positive is helping fund researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute who are tackling that question—with an approach they’re now applying to lung cancer. The team developed a faster way to identify and test treatments that help immune cells recognise and destroy cancer cells. Their first results are in lymphoma, where an experimental treatment both flags cancer cells for attack and blocks a signal that protects them. Why does this matter to our ALK community? We need more treatment options, and developing them starts with finding new ways to target cancer. This is early laboratory and animal research, not yet a treatment for ALK-positive cancer. But it shows how research supported by our community can help explore possibilities across cancer types. Read more: https://bidmc.org/news-stories/all-news-stories/news/2026/09/researchers-pioneer-faster-cancer-treatment-development

🔬 What’s next in ALK-positive cancer research? Join us Sunday, Oct. 4 at 7 PM ET for a special ALKtALK with Dr. Ken Culver exploring the research, clinical trials, and collaborations helping shape what comes next for people living with ALK-positive cancer. Dr. Culver will share updates on: • New and emerging ALK research • Clinical trials and expanding trial opportunities • A new study exploring Zepbound for lorlatinib-associated weight gain • The Global ALK Alliance and growing research collaborations We’ll also share an early preview of Lung Cancer Awareness Month and how our community can get involved this November. 💜 Whether you’re newly diagnosed, exploring future treatment options, or simply want to stay informed, bring your questions and join us live. 📅 Sunday, Oct. 4 ⏰ 7 PM ET 🔗 https://alkpositive.org/event/alktalk-oct4/ Can’t join live? The recording will be available afterward on our YouTube channel.

ALKtALK is back for Season 7! We could not be more excited to kick off Season 7 of ALKtALK with the one and only Dr. Eric Singhi of MD Anderson Cancer Center! ALKtALK Season 7 Premiere: A Fireside Chat with Dr. Eric Singhi Sunday, September 27 7:00 p.m. ET Live on Zoom | Recorded and available on YouTube You may know Dr. Singhi from social media as @lungoncdoc, where he is known for making complex cancer information accessible, engaging, and actually understandable. If you're not already following him, you should be! We'll cover the latest updates from the World Conference on Lung Cancer, while also taking it back to the basics with real-life topics that matter when you're living with ALK-positive cancer. And we want your questions, too. Bring the things you've wondered about, forgot to ask at your last appointment, or simply want an expert to weigh in on. Whether you are newly diagnosed, have been living with ALK-positive cancer for years, or are a care partner or loved one, this conversation is for you. Learn more and join the session here: https://alkpositive.org/event/alktalk-dr-eric-singhi/ #ALKtALK #ALKPositive #PatientEducation

IASLC World Congress on Lung Cancer never disappoints. From the research to the community - there is nothing like it. Among the many great meetings we were proud of so many in our community who had major roles on the stage. Our Executive Director & Medical Director Ken Culver was not only attending sessions to stay on top of the research, but meeting pharma and biotech companies to be sure we are pushing for our community. On the closing day we held our first ALK Global Alliance meeting where we convened other national ALK groups - like @alkpositivecanceraustralia @alkpositive_belgium @alkpositiveindia @alkpositivelungcanceruk, ALK Spain, other broader lung cancer groups like @aeacap @leap.sg @oncogenecancerresearch, Move Against Cancer Africa @calebegwuenu, @lcrforg @lungcancereurope, One Step Japan - and various independent, amazing advocates like @dryolaolo @shirleyjoestar and many more. Beyond the research and the science, this week was about being stronger together, pushing for better outcomes for everyone and understanding we won’t stop until we have cures. #cancer #WCLC26 #lungcancer #research #advocate

Join us for Clinical Trials Connect this Thursday, August 20, at 7:00 PM ET! Dr. Ken Culver, ALK Positive’s Executive and Medical Director, will review a year of progress in ALK research and treatment, highlighting new clinical trials, publications, and important data updates from our medical committees and collaborators. We will then open the floor to connect with community members about their clinical trial experiences, including what motivated them to participate, what the experience was like, and what they learned. Participants in TRI-611, gilteritinib, BNT-116, ivonescimab, neladalkib, and other trials are invited to share their perspectives. 📅 Thursday, August 20 ⏰ 7:00 PM ET 🔗 Join us: https://alkpositive.org/event/clinical-trial-connect-2/2026-08-20/ #ALKPositive #ClinicalTrials #StrongerTogether

World Lung Cancer Day Every cancer diagnosis changes a life. Every breakthrough changes a future. At ALK Positive, we are working toward a day when an ALK-positive lung cancer diagnosis no longer limits the time people have with those they love. Through research, education, patient support, advocacy, and a community that refuses to give up, we are helping move science forward while ensuring no one faces this disease alone. Today, on World Lung Cancer Day, we honor our community and every patient, care partner, researcher, clinician, volunteer, and advocate, like the people you see here, who continue to push for better treatments, better outcomes, and ultimately, a cure. Progress happens because people come together. Together, we are stronger. Together, we are changing what’s possible. #WorldLungCancerDay #ALKPositive #LungCancer #PatientAdvocacy #StrongerTogether

More than medicine. 💙 Another great start to our 2026 ALK Positive Summit on Sunday and we are reminded that living well with ALK+ lung cancer is about so much more than treatment. From last night’s unforgettable American Road Trip celebration to this morning’s walk through Washington, DC, we’ve celebrated friendship, resilience and the moments that make life meaningful. Today, we explored what it means to truly live well—from expert discussions on the future of ALK care, to conversations about palliative care, advocacy, care partners, and choosing your own path. Every session carried so many messages of hope and resilience. Thank you to every patient, care partner, clinician, researcher, volunteer and supporter who made this Summit so special. Here’s to continuing the conversations, the collaboration and the progress. We truly are #StrongerTogether 💙 #cancer #LungCancer #Patient

Collective

Collections

Account

Programs

Programs